Acute Leukemia, Myelodysplastic Syndrome
Conditions
Brief summary
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is regarded as a curative therapy for a variety of hematological malignancies and nonmalignant diseases. However, donor limitations have restricted the widespread use of allo-HSCT for a long period. The development and success of haploidentical allografts worldwide makes everyone has a donor a reality. In the past two decades, researchers have established several haploidentical HSCT (haplo-HSCT) protocols based on different approaches to induce immune tolerance. The representative approaches for haplo-HSCT without in vitro. T cell depletion include granulocyte colony-stimulating factor (G-CSF) plus Anti-human Thymocyte Immunoglobulin (ATG) based (Beijing Protocol) and post-transplantation cyclophosphamide based (PT-Cy, Baltimore Protocol) protocols. Both of two protocols have common problems that need to be solved, including infection transplantation related mortality and disease relapse. The main aim of this study is to explore whether the combined protocol can improve the efficacy of haploidentical transplantation further.
Interventions
DRUGReduced ATG plus mini PTCy
The conditioning protocol comprises cytarabine (Ara-C) (4 g/m2/day, days -9), busulfan (Bu) (3.2 mg/kg/day, days -8 to -6), cyclophosphamide (Cy) (1.8 g/m2/kg, days -5 and -4), simustine (250 mg/m2, day -3) and r-ATG (total 7.5mg/kg ,from days -5 to -2). Mini PTCy 14.5mg/kg/day will be given on day +3 and +4.
Sponsors
Peking University People's Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with AL - CR and/or myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplantation for the first time; 2. No gender limit, aged 12 - 65 years; 3. Planned haploidentical donor transplantation, excluding transplantation from maternal and collateral donors; 4. Eastern Cooperative Oncology Group (ECOG) performance status score≤3 points; 5. Baseline organ function tests meet the following criteria: (1) Left ventricular ejection fraction (LVEF) \> 55%; (2) Serum creatinine ≤ 1.5 × upper limit of normal (ULN).
Exclusion criteria
1. Patients with severe dysfunction of brain, heart, kidney or liver; 2. Those in refractory malignant status; 3. Patients with other malignancies requiring treatment; 4. Presence of uncontrolled severe active infection clinically; 5. Expected survival period of less than 3 months; 6. History of severe allergic reactions; 7. Pregnant or breastfeeding women; (8)Presence of any condition deemed by the investigator as unsuitable for study enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Non-relapse mortality | 100 days | None-relapse mortality within 100 days post transplantation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Regimen related toxicity | 30 days post transplantation | Regimen related toxicity will be evaluated by Bearman Criteria from the begining of conditioning to 1 month post HSCT. The organ functions that need to be assessed include the heart, liver, kidneys, cystitis, oral mucositis, and the gastrointestinal tract. |
| Engraftment | Within 30 days post transplant. Myeloid engraftment was defined as the first of three consecutive days with an ANC 0.5×109 /L, and platelet engraftment was defined as the day the platelet count met or exceeded 20×10^9 /L without transfusion for a week. | Myeloid and platelet engraftment |
| Disease relapse | 1 year post transplantation | The incidence of disease relapse |
| Disease free survival | 1 year post transplantation | The time from the start of transplantation until a patient experiences leukemia relapse or death from any cause, whichever occurs first. |
Countries
China
Contacts
Primary ContactYu Wang, M.D.
Outcome results
None listed